HeartBeam Advances Heart Attack Detection Program, Extends Cash Runway Into 2027

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company with operations in Austin, Texas, has reported its second-quarter 2026 financial and operational results, highlighting significant advancements in its heart attack detection program and initial commercial launch. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026. Additionally, HeartBeam surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study, marking a critical milestone in validating its technology for broader clinical use.

The company also announced the completion of a working prototype of its 12-lead ECG extended wear patch, a key product in its portfolio. HeartBeam has signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients, signaling the start of its commercial operations. These developments are pivotal for the company as it seeks to transform the detection and monitoring of critical cardiac conditions.

Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the prior year's net loss of $5 million, or $0.15 per share. The company's cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. Importantly, HeartBeam expects its full-year 2026 net operating cash outflow to be below $14 million, which would extend its cash runway into 2027. This financial stability provides the company with the resources needed to continue its research and development efforts and expand its commercial footprint.

HeartBeam is dedicated to creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence to physicians. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. With over 20 issued patents, HeartBeam is positioned to redefine cardiac health management by enabling physicians to identify trends and acute conditions outside of medical facilities.

The company's progress is particularly significant for Texas, where it is part of the state's thriving medical technology sector. By advancing its heart attack detection program and launching commercial operations, HeartBeam is contributing to the economic impact of the state and creating potential opportunities for healthcare providers and patients. The successful completion of its pilot studies and the development of its extended wear patch could lead to improved cardiac care and better outcomes for patients, both in Texas and globally.

For more information on HeartBeam's latest news and updates, visit the company's newsroom at https://ibn.fm/BEAT. To view the full press release, go to https://ibn.fm/QjrtT. Details on the intended use of its technology can be found at https://www.heartbeam.com/indications.